Scientists hope to double leukaemia survival rates with a new trial method backed by a £25m appeal

The approach targets blood cancers more precisely than existing treatments, aiming to cut relapse rates that currently claim thousands of lives each year in the UK.

The trial builds on breakthroughs already used in prostate cancer treatment, adapting the same 'STAMPEDE' method for blood cancers.

Researchers say current leukaemia survival rates have stagnated, and that without new funding the gap between the UK and leading countries will widen.